0.318
price down icon3.05%   -0.01
pre-market  Pre-market:  .33   0.012   +3.77%
loading
Athira Pharma Inc stock is traded at $0.318, with a volume of 1.66M. It is down -3.05% in the last 24 hours and down -27.71% over the past month. Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
See More
Previous Close:
$0.328
Open:
$0.345
24h Volume:
1.66M
Relative Volume:
6.63
Market Cap:
$12.42M
Revenue:
-
Net Income/Loss:
$-117.67M
P/E Ratio:
-0.1029
EPS:
-3.09
Net Cash Flow:
$-101.06M
1W Performance:
-9.19%
1M Performance:
-27.71%
6M Performance:
-39.78%
1Y Performance:
-87.86%
1-Day Range:
Value
$0.317
$0.3499
1-Week Range:
Value
$0.3006
$0.382
52-Week Range:
Value
$0.3006
$3.67

Athira Pharma Inc Stock (ATHA) Company Profile

Name
Name
Athira Pharma Inc
Name
Phone
(425) 620-8501
Name
Address
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Name
Employee
26
Name
Twitter
Name
Next Earnings Date
2024-12-07
Name
Latest SEC Filings
Name
ATHA's Discussions on Twitter

Compare ATHA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATHA
Athira Pharma Inc
0.318 12.42M 0 -117.67M -101.06M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Athira Pharma Inc Stock (ATHA) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-19-24 Downgrade Mizuho Outperform → Neutral
Sep-04-24 Downgrade BTIG Research Buy → Neutral
Sep-04-24 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-04-24 Downgrade Rodman & Renshaw Buy → Neutral
Aug-19-24 Initiated Rodman & Renshaw Buy
Oct-17-22 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Jul-07-22 Initiated Mizuho Buy
Jun-23-22 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-23-22 Downgrade Jefferies Buy → Hold
Jun-23-22 Downgrade Stifel Buy → Hold
May-10-22 Initiated BTIG Research Buy
Apr-21-22 Initiated Berenberg Buy
Dec-15-21 Initiated Goldman Neutral
Oct-13-20 Initiated Goldman Buy
Oct-13-20 Initiated JMP Securities Mkt Outperform
Oct-13-20 Initiated Jefferies Buy
Oct-13-20 Initiated Stifel Buy
View All

Athira Pharma Inc Stock (ATHA) Latest News

pulisher
Mar 13, 2025

What is ATHA’s price-to-sales ratio telling us about the company’s value? - US Post News

Mar 13, 2025
pulisher
Mar 11, 2025

Athira Pharma: Hold Rating Amid Strategic Uncertainty and Resource Challenges - TipRanks

Mar 11, 2025
pulisher
Mar 10, 2025

Athira Pharma stock hits 52-week low at $0.33 amid steep decline - Investing.com India

Mar 10, 2025
pulisher
Mar 07, 2025

Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga

Mar 07, 2025
pulisher
Mar 03, 2025

Athira Pharma’s Strategic Focus on ATH-1105 Amidst Uncertainties: Hold Rating Maintained - TipRanks

Mar 03, 2025
pulisher
Mar 02, 2025

Athira Pharma’s 2024 Financial Results and Pipeline Progress - MSN

Mar 02, 2025
pulisher
Feb 27, 2025

Athira Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Athira Pharma, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Can Athira's ALS Program Save the Company After $96M Cash Burn and Failed Alzheimer's Trial? - StockTitan

Feb 27, 2025
pulisher
Feb 26, 2025

Athira Pharma stock hits 52-week low at $0.41 amid steep decline - Investing.com Australia

Feb 26, 2025
pulisher
Feb 25, 2025

Athira Pharma stock hits 52-week low at $0.41 amid steep decline By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 24, 2025

Athira Pharma Inc expected to post a loss of 44 cents a shareEarnings Preview - TradingView

Feb 24, 2025
pulisher
Feb 21, 2025

ATHA INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Athira Pharma, Inc. - Marketscreener.com

Feb 21, 2025
pulisher
Feb 21, 2025

Molecular Partners (NASDAQ:MOLN) versus Athira Pharma (NASDAQ:ATHA) Head to Head Review - Defense World

Feb 21, 2025
pulisher
Feb 13, 2025

Athira Pharma (ATHA) Expected to Announce Earnings on Thursday - Defense World

Feb 13, 2025
pulisher
Jan 30, 2025

Alterity stock jumps on data for lead drug (ATHA:NASDAQ) - Seeking Alpha

Jan 30, 2025
pulisher
Jan 28, 2025

Can Athira Pharma (NASDAQ:ATHA) Afford To Invest In Growth? - Yahoo Finance

Jan 28, 2025
pulisher
Jan 21, 2025

Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct - MSN

Jan 21, 2025
pulisher
Jan 17, 2025

Insider Buyers Lose Additional US$78k As Athira Pharma Dips To US$21m - Simply Wall St

Jan 17, 2025
pulisher
Jan 14, 2025

Keeping Fraud Out of Research: Government Grant Whistleblower Awarded Over $200,000 - The National Law Review

Jan 14, 2025
pulisher
Jan 14, 2025

Will Athira Pharma See A Boost From LIFT-AD Trial Results In Alzheimer's Research? - RTTNews

Jan 14, 2025
pulisher
Jan 10, 2025

Alzheimer’s Drugmaker Athira Shells Out $4 Million In DOJ Settlement - Being Patient

Jan 10, 2025
pulisher
Jan 08, 2025

Athira to pay $4M to resolve research misconduct allegations - BioWorld Online

Jan 08, 2025
pulisher
Jan 08, 2025

ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024 - MSN

Jan 08, 2025
pulisher
Jan 08, 2025

Bothell's Athira Pharma to pay $4M to settle falsified research claims - The Business Journals

Jan 08, 2025
pulisher
Jan 07, 2025

Biotech company agrees to pay $4 million to settle data falsification allegations - Retraction Watch

Jan 07, 2025
pulisher
Jan 06, 2025

Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud - Law360

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act Allegations Related to Scientific Research - U.S. Politics Today

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma to Pay $4 Million Over Alleged Research Misconduct - Marketscreener.com

Jan 06, 2025
pulisher
Jan 06, 2025

Bothell pharma company to pay $4 million over falsified research claims - MSN

Jan 06, 2025
pulisher
Jan 06, 2025

Athira Pharma Settles Claims of NIH Research Grant Misconduct - Bloomberg Law

Jan 06, 2025
pulisher
Jan 04, 2025

Athira Pharma CEO sells shares worth $14,107 By Investing.com - Investing.com South Africa

Jan 04, 2025
pulisher
Jan 03, 2025

Athira Pharma CEO sells shares worth $14,107 - Investing.com

Jan 03, 2025
pulisher
Jan 03, 2025

Athira Pharma VP of Finance Sells Shares for $1,618 - Investing.com India

Jan 03, 2025
pulisher
Jan 03, 2025

Athira Pharma VP of Finance Sells Shares for $1,618 By Investing.com - Investing.com Canada

Jan 03, 2025
pulisher
Dec 25, 2024

JMP Securities Downgrades Athira Pharma (ATHA) - MSN

Dec 25, 2024
pulisher
Dec 18, 2024

Athira Pharma Insider Ups Holding By 111% During Year - Yahoo Finance

Dec 18, 2024
pulisher
Dec 13, 2024

Athira Pharma's SWOT analysis: stock faces challenges after trial setback - Investing.com India

Dec 13, 2024
pulisher
Dec 07, 2024

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND - The Manila Times

Dec 07, 2024
pulisher
Dec 06, 2024

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND - GlobeNewswire

Dec 06, 2024
pulisher
Nov 25, 2024

Athira Pharma, Inc. (NASDAQ:ATHA) Shares Bought by GSA Capital Partners LLP - Defense World

Nov 25, 2024
pulisher
Nov 25, 2024

Crowdstrike Holdings Inc (CRWD-Q) QuotePress Release - The Globe and Mail

Nov 25, 2024

Athira Pharma Inc Stock (ATHA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Athira Pharma Inc Stock (ATHA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
San Martin Javier
CHIEF MEDICAL OFFICER
Jan 02 '25
Sale
0.56
10,826
6,083
35,841
Litton Mark James
President and CEO
Dec 31 '24
Option Exercise
0.00
108,333
0
267,698
Litton Mark James
President and CEO
Jan 02 '25
Sale
0.56
25,107
14,108
242,591
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Dec 31 '24
Option Exercise
0.00
36,667
0
139,271
CHURCH KEVIN
CHIEF SCIENTIFIC OFFICER
Jan 02 '25
Sale
0.56
8,510
4,782
130,761
Renninger Robert
VP of Finance
Dec 31 '24
Option Exercise
0.00
12,359
0
92,605
Renninger Robert
VP of Finance
Jan 02 '25
Sale
0.56
2,881
1,619
89,724
Worthington Mark
General Counsel and CCO
Dec 31 '24
Option Exercise
0.00
36,667
0
92,245
Worthington Mark
General Counsel and CCO
Jan 02 '25
Sale
0.56
8,510
4,782
83,735
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):